Asset
ZIRITAXESTAT
Lakefront Biotherapeutics American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03733444 | phase3 | terminated | 2018-11-05 | 2021-03-30 | Lakefront Biotherapeutics NV | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care |
| NCT03798366 | phase2 | completed | 2019-01-14 | 2020-05-21 | Lakefront Biotherapeutics NV | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis |
| NCT03711162 | phase3 | terminated | 2018-11-28 | 2021-03-30 | Lakefront Biotherapeutics NV | A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care |
| NCT03976648 | phase2 | terminated | 2019-07-18 | 2021-04-13 | Lakefront Biotherapeutics NV | A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis |
| NCT03515382 | phase1 | completed | 2018-03-16 | 2018-06-01 | Lakefront Biotherapeutics NV | A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers |
FDA applications (0)
This company has no applications containing this asset.